Sunday, 14 July 2024

Taiwan Bio signs pact with US-based TRACT Therapeutics

06 December 2023 | News

To advance a novel therapeutic approach for preventing rejection in solid organ transplant

Image credit: gettyimages

Image credit: gettyimages

Taiwan Bio and US-based TRACT Therapeutics have announced new strategic partnership to advance a cellular therapy to revolutionise the prevention of allograft rejection in solid organ transplant.

The partners will launch a multi-center Phase 2 clinical trial investigating the reduction of immunosuppressant drugs in living donor kidney transplant recipients in both the United States (US) and Taiwan.

This partnership leverages Taiwan Bio’s world-class expertise in cellular therapy manufacturing and TRACT Therapeutics’ innovative immune modulating regulatory T cell therapy platform.

By combining their strengths, the companies are set to explore new frontiers in enabling allogeneic tissue transplant with a focus on enhanced patient outcomes and improved quality of life. The upcoming Phase 2 trial builds upon the promising results from a Phase 1 study which demonstrated an excellent safety profile and encouraging efficacy signals with TRACT’s autologous Treg product, TregCel.

The Phase 2 clinical trial represents the first collaborative effort between the two companies, and further updates on the trial's progress will be shared in the coming months.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account